

References

Ahmad A, Govil Y, and Frank BB: Gastric mucosa-associated lymphoid tissue lymphoma. Am J Gastroenterol.2003 May; 98(5):975-86.

Akamatsu T, Tabata K, Hironga M, et al.: Transmission of Helicobacter pylori infection via flexible fiberoptic endoscopy. Am. J. Infect. Control 1996; 24:396-401.

Akyon Y: Effect of antioxidants on the immune response of Helicobacter pylori. Drug Ther Bull 2002; 40(3):23-4.

Allum, WH, Griffin, SM, Watson A, et al.: Guidelines for the management of oesophageal and gastric cancer. Gut 2002; 50: vi-23.

Alm RA, Ling LS, Moir DT, et al.: Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 1999; 397:176-180. [Erratum, Nature 1999 397:719.]

Alsolaiman-MM, Bakis G, Nazeer T, et al.: Five years of complete remission of gastric diffuse large B cell lymphoma after eradication of Helicobacter pylori infection.Gut 2003; 52:507-509.

Ando T, Tsuzuki T, Mizuno T, et al.: Characteristics of Helicobacter pylori-induced gastritis and the effect of H. pylori eradication in patients with chronic idiopathic thrombocytopenic purpura Helicobacter 2004 Oct; 9 (5):443-52.

Andrews NC, and Bridges KR: Disorders of iron metabolism and sideroblastic anemia. In Nathan DG, Orkin SH, eds. Nathan and Oski's hematology of infancy and childhood. 5th ed. Vol.1 Philadelphia: W.B. Saunders, 1998:423-61.

Andrews NC: Disorders of Iron Metabolism. N Engl J Med 1999; 341:1986-1995.

Andrews PA, Green R, Conrad ME, et al.: Disorders of Iron Metabolism. N Engl J Med 2000 342:1293-1294.

Annibale B, Capurso G, and Delle Fave G: The stomach and iron deficiency anaemia: a forgotten link.Dig Liver Dis. 2003; 35:288-95.

Annibale B, Capurso G, Chistolini A, et al.: Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms. Am J Med (2001a); 111: 439-45.

Annibale B, Lahner E, Bordi C, et al.: Role of Helicobacter pylori infection in pernicious anaemia. Dig Liver Dis. 2000; 32:756-62.

Annibale B, Marignani M, Monarca B, et al.: Reversal of iron deficiency anaemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med 1999;131:668-72.

Annibale B, Negrini R, Caruana P, et al.: Two-thirds of atrophic body gastritis patients have evidence of Helicobacter pylori infection. Helicobacter 2001; 6:225-33.

anti-CagA antibodies in rosacea patients. *Int J Dermatol* 2003; 42: 601-4.

Armuzzi A, Cremonini F, Ojetto V, et al.: Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during *Helicobacter pylori* eradication therapy: a pilot study. *Digestion* 2001; 63:1-7.

Asaka M and Dragosics BA: *Helicobacter pylori* and Gastric Malignancies. *Helicobacter* 2004; 9(1):35-41.

Athmann C, Zeno N, Kang T, et al.: Local pH elevation mediated by the intrabacterial urease of *Helicobacter pylori* cocultured with gastric cells. *J Clin Invest.*2000; 106:339-347.

Avenaud P, Marais A, Monteiro L, et al.: Detection of *Helicobacter* species in the liver of patients with and without primary liver carcinoma. *Cancer* 2000; 89:1431-1439.

Aydin A, Ersoz G, Tekesin O, et al.: Garlic oil and *Helicobacter pylori* infection. *Am. J. Gastroenterol.*2000; 95:563-564.

Baker E and Morgan EH: Iron transport. In: Brock JH, Halliday JW, Morgan MJ, Powell LW, (eds). *Iron metabolism in health and disease*. London: WB Saunders 1994.

Barabino A: *Helicobacter pylori*-related iron deficiency anemia: a review. *Helicobacter*.2002 7:71-75.

Barnard FM, Loughlin MF, Fainberg HP, et al.: Global regulation of virulence and the stress response by CsrA in the highly adapted human gastric pathogen *Helicobacter pylori*. *Mol Microbiol* 2004 51: 15-32.

Bartuzi Z, Gawrokska-Ukleja E, RomaAski B: Macroscopic picture of gastric mucosa in endoscopic examination of patients with chronic gastritis and food allergy. *Med Sci Monit* (2000); 6(6) 1203-1208.

Bazzoli F: Key points from the revised Maastricht Consensus Report: the impact on general practice. *Eur J Gastroenterol Hepatol* 2001; 13: Suppl 2:S3-S7.

Beales I, Srinivasan S, Blaser M, et al.: Effect of *Helicobacter pylori* constituents and inflammatory cytokines on gastrin release from isolated canine G cells. *Gastroenterology* 1995; 108 A779.

Beard J and Tobin B: Iron status and exercise. *American Journal of Clinical Nutrition* 2000 72:594S-597S.

Bebb JR, Letley DP, Thomas RJ, et al.: *Helicobacter pylori* upregulates matrix metalloproteinase-7 in epithelial cells in vivo and in vitro in a Cag dependent manner. *Gut* 2003; 52: 1408-13.

Becker BF: Towards the physiological function of uric acid. *Free Radic Biol Med* 1993;14:615-631.

of patients with diabetes type I and 111.' [abstract]. Gastroenterology 1998; 114:A71.

Berg G, Bode G, Blettiner M, et al.: Helicobacter pylori infection and serum ferritin: population based study among 1806 adults in Germany. Am J Gastroenterol 2001; 96:1014-19.

Bini EJ. Helicobacter pylori and iron deficiency anaemia: guilty as charged? Am J Med 2001 111:495-7.

Blanchard TG and Czinn SJ: Immunology of Helicobacter pylori and prospects for vaccine Gastroenterol Clin North Am 2000; 29:671685.

Bothwell TH, Baynes RD, McFarlane BJ, et al.: Nutritional iron requirements and food iron absorption. J Int Med 1989; 226:357-65.

Brittenham GM, Weiss G, Brissot P, et al.: Clinical Consequences of New Insights in the Pathophysiology of Disorders of Iron and Heme Metabolism. Hematology 2000; 1: 39 - 50.

Brittenham GM: Disorders of iron metabolism: iron deficiency and overload. In: Hoffman R Shattil SJ, Furie B, Cohen HJ, Silberstein

LE, McGlave P, eds: Hematology: Basic Principles and Practice (ed 3rd). New York: Churchill Livingstone; 2000: 397 -428

Brown LM: Helicobacter pylori: epidemiology and routes of transmission. Epidemiol. Rev 2000; 22:283-297.

Buhling F, Koch G, Wex T, et al.: Simultaneous detection and differentiation of anti Helicobacter pylori antibodies by flow microparticle immunofluorescence assay. Clin Diagn Laborator Immunol 2004; 11: 131-6.

Campbell JD, Cole M, Bunditruvorn B, et al.: Ascorbic acid is a potent inhibitor of various forms of T cell apoptosis. Cell Immunol. 1999; 194:1-5.

Capurso G, Lahner E, Marcheggiano A, et al.: Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated with Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15:1753-62.

Capurso G, Ricci R, Panzuto F, et al.: Intragastric ascorbic but not uric acid is depleted in relation with the increased pH in patients with atrophic body gastritis and H. pylori gastritis. Helicobacter 2003; 8(4):300-6.

Carley A: Anemia: when is it iron deficiency? Pediatr Nurs.2003; 29:127-33.

Carnahan MA and Kaplan LR: Vibrio, Aeromonas, Plesiomonas and Compylobacter In: Mahon CR and Manuselis G (eds.), Diagnostic Microbiology. Philadelphia, London Toronto, Montreal and Tokyo, Saunders Company. P.P. 1995; 505-512.

Cassar K, Bachoo P, Ford 1, et al.: Helicobacter pylori seropositivity is associated with enhanced platelet activation in patients with intermittent claudication. J Vasc Surg 2004; 39: 560-4.

receptor as a potential determinant of iron loading in congenital anaemias due to ineffective erythropoiesis. *Br J Haematol.* 1999; 106:752-755.

Censini S, Lange C, Xiang ZY, et al.: Cag, a pathogenicity island of *Helicobacter pylori*, encodes type I-specific and disease-associated virulence factors. *Proc. Natl Acad. Sci. USA* 1996; 93:14648-14653.

Choe YH, Hwang TS, Kim HJ, et al.: A possible relation of the *Helicobacter pylori* pfr gene to iron deficiency anemia. *Helicobacter* 2001; 6:55-59.

Choe YH, Kim SK, and Ilona VC: *Helicobacter pylori* infection with iron deficiency anaemia and subnormal growth at puberty. *Arch Dis Child* 2000; 82:136-40.

Choe YH, Kim SK, Son BK, et al.: Randomized placebo-controlled trial of *Helicobacter pylori* eradication for iron-deficiency anaemia in preadolescent children and adolescents. *Helicobacter* 1999 4:135-9.

Choe YH, Kwon YS, Jung MK, et al.: *Helicobacter pylori*-associated iron-deficiency anemia in adolescent female athletes. *J Pediatr.* 2001a; 139:1004.

Coelho LG, Leon-Barua R, and Quigley EM: Latin-American Consensus Conference on *Helicobacter pylori* infection. *Am J Gastroenterol.* 2000; 95:2688-2691.

Conrad ME, Umbreit JN, and Moore EG: Iron absorption and transport. *Am J Med Sci* 1999 318:213-19.

Conrad ME, Umbreit JN, and Moore EG: A role for mucin in the absorption of inorganic iron and other metal cations. A study in rats.

Gastroenterology 1991; 100: 129-36.

Cook JJ, and Monson ER: Vitamin C, the common cold, and iron absorption. *Am J Clin Nut* 1977; 30:235-41.

Corthesy-Theulaz I, Corthesy B, et al.: Naked DNA immunization against *Helicobacter* infection. *Gastroenterology* 1996; 110:A889.

Courillon M A, Launay JM, Roucayrol AM, et al.: *Helicobacter pylori* infection: physiopathologic implication of N (x-methyl histamine. *Gastroenterology* 1995; 108:959-966.

Cover TL, Glupczynski Y, Lage AP, et al.: Serologic detection of infection with cagA of *Helicobacter pylori* strains. *J. Clin. Microbiol.* 1995; 33:1496-1500.

Cover TL, Tuniniurit MK, Cao P, et al.: Divergence of genetic sequences for the vacuolating cytotoxin among *Helicobacter pylori* strains. *J. Biol. Chem.* 1994; 269:10566-10573.

Crabtree JE: Role of cytokines in pathogenesis of *Helicobacter pylori* induced mucosal damage. *Dig Dis Sci* 1998; 43 (Suppl 9): 46-55.

iron-deficiency anaemia in patients with coeliac disease. *Scand J Gastroenterol.* 2001; 36:1284-1288.

Cutler A, Schubert A, and Schubert T: Role of *Helicobacter pylori* serology in evaluating treatment success. *Dig. Dis. Sci.* 1993; 38:2262-2266.

Cutler AF, Haystad S, Ma CK, et al.: Accuracy of invasive and non-invasive tests to diagnose *Helicobacter pylori* infection. *TL Gastroenterology* 1995; 109:13-6-141.

Cutler AF: Eradicating *Helicobacter pylori* infection. *Patient Care* 2001; 15:91-100.

Davies GR, Banatvala N, Collins CE, et al.: Relationship between infective load of *Helicobacter pylori* and reactive oxygen metabolite production in antral mucosa. *Scand. J. Gastroenterol.* 1994; 29:419-424.

Day AS, Veldhuyzen van Zanten S, Otley AR, et al.: Use of LARAurea breath test in the diagnosis of *Helicobacter pylori* infection in children and adolescents: a preliminary study. *Can. J. Gastroenterol* 2003; 17: 701-6.

De Boer WA, van Etten RJ, Schade IM, et al.: 4-day lansoprazole quadruple therapy: a highly effective cure for *Helicobacter pylori* infection. *Am. J. Gastroenterol.* 1996; 91:1778-1782.

De Luca C, Filosa A, Grandinetti M, et al.: Blood antioxidant status and urinary levels of catecholamine metabolites in beta-thalassemia. *Free Radic Res* 1999; 30:453-62

Degnan AJ, Sonzogni WC, and Standridge JH: Development of a plating medium for selection of *Helicobacter pylori* from water samples. *Appl Environ Microbiol* 2003; 69: 2914-8.

Del Giudice G and Michetti P: Inflammation, immunity and vaccines for *Helicobacter pylori*. *Helicobacter* 2004; 9 Suppl 1:23-8.

D'Elia MM, Amedei A, and Del Prete G: *Helicobacter pylori* antigen-specific T-cell response at gastric level in chronic gastritis, peptic ulcer, gastric cancer and low-grade mucosa-associated lymphoid tissue (MALT) lymphoma. *Microbes Infect.* 2003 Jul; 5(8):723-30.

Demir H, Saltik IN, Kodak N, et al.: Subnormal growth in children with *Helicobacter pylori* infection. *Arch. Dis. Child.*, January 1, 2001; 84(1): 89b - 89.

Deprez P and Calam J: Mechanisms in hypergastrinemia in autoimmune atrophic gastritis and *Helicobacter pylori* infection. *Acta Gastroenterol Belg.* 1993; 56:245-50.

Dickey W, Kenny BD, McMillan SA, et al.: Gastric as well as duodenal biopsies may be useful in the investigation of iron deficiency anaemia. *Stand J Gastroenterol* 1997;32:460-72.

Dickey W: Iron deficiency, gastric atrophy and *Helicobacter pylori*. *Dig Liver Dis* 2002; 34:313-15.

Dixon MF, Genta RIM, Yardley JH, et al.: Classification and grading of gastritis- the updated Sydney system. *Am. J. Surg. Pathol.* 1996; 20:1161-1181.

infection in patients with pernicious anemia. *Folic Med (Plovdiv)*. 2000; 42(2):23-7.

Donovan A, Brownlie A, Zhou Y, et al.: Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter. *Nature*. 2000; 403:776-781.

Dore MP, Leandro G, Realdi G, et al.: Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of *Helicobacter pylori* therapy: a meta-analytical approach. *Dig Dis Sci* 2000; 45:68-76.

Dore INTP, Sepulveda AR, El-Zin. kity H, et al.: Isolation,,- *Helicobacter pylori* from sheep: implications for transmission to humans. *Am J Gastroenterol*. 2001; 96:1396-1401.

Drake I, Mapstone N, Schorah C, et al.: Reactive oxygen species activity and lipid peroxidation in *Helicobacter pylori* associated (Yastritis: relation to Gastric mucosal ascorbic acid concentrations and effect of *H. pylori* eradication. *Gut*, 1998; 42: 768-771 .

Dubos F, Gottrand F, Devisme L, et d.: The end of *Helicobacter pylori* as a hypothetical cause of SIDS. *Am J Gastroenterol* 2003; 98: 1206-7.

Dundon WG, Nishioka 11, Polenghi Act al.: The neutrophil-activating protein of *Helicobacter pylori*. *Pediatr Int*. 2002; 44(3):277-80.

Dunn BE, Cohen H, and Blaser MJ: *Helicobacter pylori*. *Clinical Microbiology Reviews* 1997 10:720-741.

Eaton KA, Mefford M, and Thevenot T: The role of T cell subsets and cytokines in the pathogenesis of *Helicobacter pylori* gastritis in mice. *J Immunol* 2001; 166:7456-61.

El-Fiky MAF: Fresh look on *Helicobacter pylori* Internal Medicine, Faculty of Medicine, Cairo University, 2000.

El-Mashad NBI: *Helicobacter pylori* and gastric disorder. Clinical Pathology Department Faculty of Medicine, Mansoura University, 1995.

El-Omar EM, Oien K, El-Nujurni A, et al.: *Helicobacter pylori* infection and chronic gastric acid hyposecretion. *Gastroenterology* 1997;113:15-24.

El-Omar EM, Rabkin CS, Gammon MD, et al.: Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. *Gastroenterology* 2003; 124: 1103-20 1.

El-Zimaity HM, al-Assi MT, Genta RM, et al.: Confirmation of successful therapy of *Helicobacter pylori* infection: number and site of biopsies or a rapid urease test. *Am. J. Gastroenterol* 1995; 90:1962-1964.

Everett SM, Singh R, Leuratti C, et al.: Levels of malondialdehydedeoxyguanosine in the gastric mucosa: relationship with lipid peroxidation, ascorbic acid, and *Helicobacter pylori*. *Cancer Epidemiol Biomarkers Prev* 2001; 10:369-76.

Foundation Task Force, ed. Iron: nutritional and physiological significance. London: Chapman and Hall 1995.

Faller G, and Kirchner T: Role of antigastric autoantibodies in chronic *Helicobacter pylori* infection. *Microsc Res Tech.* 2000 Mar 15; 48(6):321-6.

Falush D, Kraft C, Taylor NS, et al.: Recombination and mutation during long-term gastric colonization by *Helicobacter pylori*: estimates of clock rates, recombination size, and minimal age. *Proc Natl Acad Sci USA* 2001; 98:15056-15061.

Farinati F, Cardin R, Russo VM, et al.: *Helicobacter pylori* CagA status, mucosal oxidative damage and gastritis phenotype: a potential pathway to cancer? *Helicobacter* 2003; 8: 227-34

Feldman RA: Epidemiologic observations and open questions about disease and infection caused by *Helicobacter pylori*. In: Achtman M, Suerbaum S, (eds). *Helicobacter pylori: molecular and cellular biology*. Wymondham, United Kingdom: Horizon Scientific Press, 2001:29-51.

Finch C: Regulators of iron balance in humans. *Blood.* 1994; 84:1697-1702.

Fischer W, Pfils J, Buhrdorf R, et al.: Systematic mutagenesis of the *Helicobacter pylori* cag pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin-8. *Mol Microbiol* 2001; 42:1337-1348.

Frewin R, Henson A and Provan D: ABC of Clinical haematology: Iron deficiency anaemia. *BMJ* 1997; 314:360.

Frieri G, Pimpo MT, Palombieri A, et al.: Polyunsaturated fatty acid dietary supplementation as an adjuvant approach to treatment of *Helicobacter pylori* infection. *Nutr Res* 2000; 20:907-916.

Futagami S, Hiratsuka T, Tatsuguchi A, et al.: Monocyte chemoattractant protein 1 (MCP-1) released from *Helicobacter pylori* stimulated gastric epithelial cells induces cyclooxygenase-2 expression and activation in T cells. *Gut* 2003; 52:1257-1264.

Gaby AR: *Helicobacter pylori* Eradication: Are there Alternatives to Antibiotics? *Altern Med Rev.* 2001; 6:355-6.

Garcia-Gonzalez MA, Lanas A, Savelkoul PH, et al.: Association of interleukin I gene family polymorphisms with duodenal ulcer disease. *Clin Exp Immunol* 2003; 134: 525-31.

Gasbarini A, Franceschi F, De Miquel DB, et al.: Role of *Helicobacter pylori* in extradigestive diseases. *Curr. Opin. Gastroenterol.* 1999; 15: 29-33.

Gasbarrini A, Carloni E, Gasbarrini G, et al.: *Helicobacter pylori* and extragastric diseases other *Helicobacters*. *Helicobacter* 2004; 9 (1): 57-66.

Giannini E, Fasoli A, Botta F, et al.: *Helicobacter pylori* infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients. *Dig Dis Sci* 2003; 48: 802-8.

omeprazole is related to H. pylori status (abstract). Gastroenterology 1997; 112:A126.

Giusti C: Central serous chorioretinopathy: a new extragastric manifestation of Helicobacter pylori?: Analysis of a clinical case Clin Ter. 2001;152(6):393-7.

G66z M, Shaker M, G66z P, et al.: Interleukin 113 induces gastric epithelial cell matrix metalloproteinase secretion and activation during Helicobacter pylori infection. Gut 2003; 52: 1250-1256.

Graham DY, de Boer WA, and Tytgat GN: Choosing the best anti-Helicobacter pylori therapy in the presence of antimicrobial resistance. Am. J. Gastroenterol. 1996; 91:1072-1076.

Grosbois B and Gatel A: Diagnosis and treatment of iron deficiency. Rev Prat. 2000; 50:966-71.

Gurbuz AK, Ozel AM, Yazgan Y, et al.: Oral colonization of Helicobacter pylori: risk factor and response to eradication therapy. South Med J 2003; 96: 244-7.

Guruge JL, Falk PG, Lorenz RG, et al.: Epithelial attachment alters the outcome of Helicobacter pylori infection. Proc Natl Acad Sci U S A 1998; 95:3925-3930.

Gutierrez 01 Melo M, Graham DY, et al.: Improved acid secretion after treatment of H. pylori infection: time course (abstract). Gastroenterology 1997; 112:A136.

Hachem CY, Clarridge JE, Evans DG, et al.: Comparison of agar based media for primary isolation of Helicobacter pylori. J. Clin. Pathol. 1995; 48:714-716.

Hallberg L, Brune M, and Rossander L: Effect of ascorbic acid on iron absorption from different types of meals. Studies with ascorbic acid-rich foods and synthetic ascorbic acid given in different amounts with different meals. Hum Nutr Appl Nutr 1986; 40:97-113.

Han SW, Flamm R, Hachem CY, et al.: Transport and storage of Helicobacter pylori from gastric mucosal biopsies and clinical isolates. Eur. J. Clin. Microbiol. Infect. Dis. 1995; 14:349-352.

Harris PIZ, Godoy A, Arenillas S, et al.: CagA antibodies as a marker of virulence in Chilean patients with Helicobacter pylori infection. J Pediatr Gastroenterol Nutr 2003;37: 596-602.

Harris PR, Smythies LE, Smith PD, et al.: Inflammatory cytokine mRNA expression during early and persistent Helicobacter pylori infection in nonhuman primates. J Infect Dis 2000; 181:783-786.

Hayashi S, Sugiyama T, Amano K-1, et al.: Effect of Rebamipide, a Novel Antiulcer Agent, on Helicobacter pylori Adhesion to Gastric Epithelial Cells. Antimicrobial Agents and Chemotherapy 1998; 42:1895-1899.

Higashi H, Tsutsumi R, Muto S, et al.: SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 295:683-686.

Hiramoto S, Itoh K, Shizuuchi S, et al.: Melanoidin, a food protein-derived advanced Maillard reaction product, suppresses Helicobacter pylori in vitro and in vivo. Helicobacter. 2004 Oct; 9(5):429-35.

treatment. *J. Gastroenterol.* 1996; 31:33-36.

Hockey M and Weidenmann B: Molecular mechanisms of enteroendocrine differentiation. *Am N Y Acad Sci.* 1998; 859:160174.

Hofman P, Waidner B, Hofman V, et al.: Pathogenesis of *Helicobacter pylori* Infection *Helicobacter* 2004; Suppl (9)1:15-22.

Hojo M, Miwa H, Nagahara A, et al.: Pooled analysis on the efficacy of the second-line treatment regimens for *Helicobacter pylori* infection. *Scand J -Gastroenterol* 2001; 36:690-700.

Hong W, Sano K, Morimatsu S, et al.: Medium pH-dependent redistribution of the urease of *Helicobacter pylori*. *J Med Microbiol* 2003; 52: 211-216.

Hosking SW, Ling TK, Yung MY, et al.: Randomized controlled trial of short term treatment to eradicate *Helicobacter pylori* in patients with duodenal ulcer. *B.M.J.*1992; 305:502-504.

Hunt JR and Roughead ZK: Adaptation of iron absorption in men consuming diets with high or low iron bioavailability. *Am J Clin Nutr.* 2000; 71:94-102.

Hurrell RF, Juillerat MA, Reddy MB, et al.: Soy protein, phytate, and iron absorption in humans. *Am J Clin Nutr* 1992; 56:573-578.

Husson MO, Legrand D, Spik G, et al.: Iron acquisition by *Helicobacter pylori*: importance of human lactoferrin. *Infect Immun.* 1993; 61:2694-7.

Huwez FU, Thirlwell D, Cockayne A, et al.: Mastic gum kills *Helicobacter pylori*. *N Engl J Med* 1998; 339:1946.

Ikkala E, Salmi IJ, and Siurala M: Gastric mucosa in iron deficiency anaemia. Results of follow-up examinations. *Acta Haematol* 1970;43:228-31.

Inoue M., Kobayashi S., Matsuura A., et al.: Agreement of endoscopic findings and serum pepsinogen levels as an indicator of atrophic gastritis. *Cancer Epidemiol. Biomark. Prev.*, 7: 261-263 1998.

Ito K, Nakamura M, Toda G, et al.: Potential role of *Helicobacter pylori* in hepatocarcinogenesis. *Int J Mol Med* 2004; 13: 221-7.

Ito M, Haruma K, Kaya S, et al.: Role of anti-parietal cell antibody in *Helicobacter pylori* associated atrophic gastritis: evaluation in a country of high prevalence of atrophic gastritis. *Scand J Gastroenterol.* 2002; 37:287-93.

Iwata H, Nishio S, Yokoyama M, et al.: Solubility of uric acid and super-saturation of monosodium urate: why is uric acid so highly soluble in urine? *J Urol* 1989; 142:1095-8.

Jaki2e-Razurnovix J, Tentor D, Kugec V, et al.: Histopathological Features of Gastritis before and after Treatment for *Helicobacter pylori*. *Clin Sci* (2000); 41(2):159-162.

between coccoid forms of *Helicobacter pylori* and gastric epithelial cells. *Am. J. Gastroenterol* 1995;90:1829-1833.

Jarosz M, Dzieniszewski J, Dabrowska-Ufniaż E, et al.: Effects of high dose vitamin C treatment on *Helicobacter pylori* infection and total vitamin C concentration in gastric juice. *Tier J Cance Prev*1998; 7:449-54.

Jorgensen M, Daskalopoulos G, Warburton V, et al.: Multiple strain colonization and metronidazole resistance in *Helicobacter pylori*-infected patients: identification from sequential and multiple biopsy specimens. *J. Infect. Dis.*1996; 174: 631-635.

Josenhans C and Suerbaum S: *Helicobacter* motility and chemotaxis. In: Achtman M, Suerbaum S, eds. *Helicobacter pylori: molecular and cellular biology*. Wymondham, United Kingdom: Horizon Scientific Press,2001:171-84.

Kabir S. Review article: clinic-based testing for *Helicobacter pylori* infection by enzyme immunoassay of faeces, urine and saliva. *Aliment Pharmacol Ther.* 2003 Jun 1; 17(11):1345-54.

Kaptan K, Beyan C, Ural AU, et al.: *Helicobacter pylori*--is it a novel causative agent in Vitamin B12 deficiency? *Arch Intern Med.* 2000 May 8; 160(9):1349-53.

Karamizrak SO, Islegen C, Varol SR, et al.: Evaluation of iron metabolism indices and their relation with physical work capacity in athletes. *Br J Sports Med* 1996; 30:15-9.

Kim DY and Back JY: The comparison of histologic gastritis in patients with duodenal ulcer, chronic gastritis, gastric ulcer and gastric cancer. *Yonsei Med J.* 1999 Feb; 40(1):14-9.

Klein PD, Malaty HM, Martin RF, et al.: Noninvasive detection of *Helicobacter pylori* infection in clinical practice: the 13 C urea breath test. *Am. J. Gastroenterol.* 1996; 91:690- 694.

Kodama K, Sumii K, Kawano M, et al.: *Helicobacter pylori* infection.

Koike T, Ohara S, Sekine H, et al.: *Helicobacter pylori* infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. *Gut* 2001; 49: 330-334.

Kountouras J, Zavos C, and Chatzopoulos D: Induction of apoptosis as a proposed pathophysiological link between gastric cancer and *Helicobacter pylori* infection. *Med Hypotheses* 2004; 62 378-81.

Kuipers EJ, and Malfertheiner P: *Helicobacter pylori* and nonmalignant diseases. *Helicobacter* 2004; Suppl (9) 1:29-34,

Lacy BE and Rosemore J: *Helicobacter pylori: Ulcers and More: The Beginning of an Era* *Journal of Nutrition.* 2001; 131:27895-27935.

Laine L, Estrada R, Trujillo M, et al.: Randomized comparison of ranitidine bismuth citrate (RBC) based triple therapies for *H. pylori* (HP). *Gastroenterology* 1997; 112:AI92.

ulcer dyspepsia. *Ann. Int. Med.*2001; 134:361-369.

Lehours P, Menard A, Dupouy S, et al.: Evaluation of the association of nine *Helicobacter pylori* virulence factors with strains involved in low-grade gastric mucosa associated lymphoid tissue lymphoma. *Infect Immun* 2004; 72: 880-8.

Leontiadis G1, Sharma VK, and Howden CW: Non-Gastrointestinal Tract Associations of *Helicobacter pylori* Infection. *Arch Intern Med* 1999; 159:925-940.

Leung AK, and Chan KW: Iron deficiency anemia. *Adv Pediatr.*2001; 48:385-408.

Levi S, Breadshall K, Haddad G, et al.: *Campylobacter pylori* and duodenal ulcers: the gastrin link. *Lancet* 1989; i: 1167-1168.

Lev C, Mohar A, Guarner J, et A.: Screening Markers for Chronic Atrophic Gastritis in Chiapas Mexico. *Cancer Epidemiology Biomarkers & Prevention* 2001; 10:107-112.

Liutu M, Kalimo K, Kalimo H, et al.: Mast cells and IgE-containing cells in gastric mucosa of *Helicobacter pylori* infected and non-infected patients with chronic urticaria. *J Eur Acad Dermatol Venereol* 2004; 18: 69-72.

Logan ECM, Yates JM, Stewart RM, et al.: Investigation and management of iron deficiency anaemia in general practice: a cluster randomised controlled trial of a simple management prompt. *Postgrad Med J* 2002; 78: 533-537.

Logan RP and Walker MM: ABC of the upper gastrointestinal tract. Epidemiology and diagnosis of *Helicobacter pylori* infection. *BMJ* 2001; 323:920-922.

Lombard M, Chua E, and O'Toole P: Regulation of intestinal nonhaem iron absorption. *Gut* 1997; 40:435-439.

Ma JY, Borch K, Sjostrand SE, et al.: Positive correlation between H,K-adenosine triphosphatase autoantibodies and *Helicobacter pylori* antibodies in patients with pernicious anemia. *Scand J Gastroenterol.* 1994; 29:961-5.

MacKay WG, Williams CL, McMillan M, et al.: Evaluation of protocol using gene capture and PCR for detection of *Helicobacter pylori* DNA in feces. *J Clin Microbiol* 2003; 41: 458993.

Makristathis A, Hirsch AM, Lehours P, et al.: Diagnosis of *Helicobacter pylori* Infection. *Helicobacter* 2004; 9 Suppl 1:7-14.

Manes G, Balzano A and Vaira D: *Helicobacter pylori* and Pancreatic-Disease. *J Pancreas* 2003; 4(3):111-116.

Mannick EE, Bravo LE, Zararna G, et al.: Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in *Helicobacter pylori* gastritis: effect of antibiotics and antioxidants. *Cancer Res.* 1996 56:3238-3243.

Helicobacter pylori-associated atrophic gastritis. *Dig Dis Sci*. 1999; 44:680-685.

Marcus EA and Scott DR: Cell lysis is responsible for the appearance of extracellular urease in *Helicobacter pylori*. *Helicobacter* (2001); 6: 93-99.

Marignani M, Angeletti S, Antonelli G, et al.: Absorption of the oral iron preparation ferrous acetyl transferrin in achlorhydric patients: a pilot study. *Cur• Ther Res*. 1996; 57:544-51.

Marignani M, Delle rive G, Mccarocci S, et al.: High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia: a prospective screening study. *Am J Gastroenterol*. 1999; 94:766-772.

Marshall B and Warren JR: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984; 1:1311-1315.

Matsuda M, Noda Y, and Takemori Y: Novel diagnostic method of testing for *Helicobacter pylori* infection using the rapid leukocyte strip test, Leukostix. *J Gastroenterol Hepatol* 2003;18: 1196-201.

Matysiak-Budnik T, Heyman M and Megraud F: Rebamipide and the digestive epithelial barrier. *Aliment Pharmacol Ther*. 2003; 1:55-62.

McColl KE, El-Omar E and Gillen D: *Helicobacter pylori* gastritis and Gastric physiology. *Gastroenterol Clin North Am* 2000; 29:687-703.

McKie AT, Marciani P, Rolfs A, et al.: A novel duodenal iron regulated transporter, IREG1 implicated in the basolateral transfer of iron to the circulation. *Mol Cell* 2000; 5: 299 -309.

Megraud F, Hazell S and Glupczynski Y: Antibiotic susceptibility and resistance. In: Mobley HLT, Mendz GL, Hazell SL, eds. *Helicobacter pylori: physiology and genetics*. Washington, D.C.: ASM Press, 2001:511-30.

McIning A, Stolle M, Hatz R, et A.: Differing degree and distribution of gastritis in *Helicobacter pylori*-associated diseases. *Virchows Arch*. 1997;431:1-5.

Meyer JM, Hopkins RJ, Mascitelli L, et al.: *Helicobacter pylori*. *N Engl J Med* 2003; 348: 363-365.

Meyer JM, Silliman NP, Wang W, et al.: Risk factors for *Helicobacter pylori* resistance in the United States: the Surveillance of *H. pylori* Antimicrobial Resistance Partnership (SHARP) study, 1993-1999. *Ann Intern Med* 2002; 136:13-24.

Michel M, Cooper N, Jean C, et al.: Does *Helicobacter pylori* initiate or perpetuate immunothrombocytopenic purpura? *Blood* 2004; 103: 890-6.

Migneco A, Ojetti V, Specchia L, et al.: Eradication of *Helicobacter* infection improves blood pressure values in patients affected by hypertension. *Helicobacter* 2003; 8: 585-9.

pylori infection: A seroepidemiologic survey comprising 2794 Danish adults. *Gastroenterology* 1998; 115:268-74.

Misiewicz JJ, Harris AW, Bardhan KD, et al.: One week low dose triple therapy for eradication of *H. pylori*. A large multicenter randomized trial. *Gastroenterology* 1996; 110:A198.

Miwa H, Go MF, and Sato N: *H. pylori* and gastric cancer: the Asian enigma. *QJM*. 2002; 95(8):519-25.

Miyagi H, Ito S, Azuma T, et al.: Effects of *Helicobacter pylori* eradication therapy on hyperammonemia in patients with liver cirrhosis. *Gut* 1997; 40:726-730.

Moayyedi P, Carter AM, Braunholtz D, et al.: *Helicobacter pylori* infection in subjects with acute ischaemic stroke. *Dig. Liv. Dis.* 2003; 10:10-19.

Moayyedi P, Carter AM, Catto A, et al.: Validation of a rapid whole blood test for diagnosing *Helicobacter pylori* infection. *BMJ* 1997; 314:119.

Mobley HL: *Helicobacter pylori* urease. In: Achtman M, Suerbaum S, eds. *Helicobacter pylori* molecular and cellular biology. Wymondham, United Kingdom: Horizon Scientific Press, 2001:155-170.

Montecucco C, and de Bernard M: Molecular and cellular mechanisms of action of the vacuolating cytotoxin (VacA) and neutrophil-activating protein (HP-NAP) virulence factors of *Helicobacter pylori*. *Microbes Infect* 2003; 5: 715-21.

Mooney C, Keenan J, Munster D, et al.: Neutrophil activation by *Helicobacter pylori*. *Gut* 1991; 32:853-7.

Moran AP: The role of lipopolysaccharide in *Helicobacter pylori* pathogenesis. *Aliment Pharmacol. Ther.* 1996; 10(Suppl. 1):39-50.

Morgan C, Jenkins GJ, Ashton T, et al.: Detection of p53 mutations in precancerous gastric tissue. *Br J Cancer* 2003; 89: 131.1-9.

Morris A., Ali M.R., Nicholson M.R., et al.: Long-term follow up of voluntary ingestion of *Helicobacter pylori*. *Ann. Intern. Med.* (1991); ingestion

Mowat C, Carswell A, Wirz A, et al.: Omeprazole and dietary nitrate independently affect level of vitamin C and nitrite in gastric juice. *Gastroenterology* 1999; 116:813-22.

Mukhopadhyay CK, Mazumder B, and Fox PL: Role of hypoxia inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. *J Biol Chem.* 2000; 275:21048-21054.

Naficy AB, Frenck RW, Abu-Elyazeed R, et al.: Seroepidemiology of *Helicobacter pylori* infection in a population of Egyptian children. *International Journal of Epidemiology* 2000; 29:928-932.

Nahon S and Bouhnik Y: Investigation of iron deficiency. *Gastroenterol Clin Biol.* 2000; 24:B627.

Unexplained Iron Deficiency Anemia: a Reliable Association? *Helicobacter* 2003; 8 (6), 573-577.

Negrini R, Savio A, and Appelmelk BJ: Autoantibodies to gastric mucosa in *Helicobacter pylori* infection. *Helicobacter* 1997; 2: S13- 16.

Negrini R, Savio A, Poiesi CA, et al.: Antigenic mimicry,pen *Helicobacter pylori* and gastri mucosa in the pathogenesis of body atrophic gastritis. *Gastroenterol.* 1996; 111:655-665.

Neu B, Randlkofer P, Neuhofer M, et al.: *Helicobacter pylori* induces apoptosis of rat gastri parietal cells. *Am J Physiol Gastrointest Liver Physiol* 2002; 283: G309 - 318.

Nobelprize.org, press release, 2005; Web site.

Novak J, Szekanecz Z, Sebesi J, et al.: Elevated levels of a4nti *Helicobacter pylori* antibodies i Henoch-Schonlein purpura. *Autoimmunity* 2003; 36: 307-11.

Nozaki K, Shimizu N, Ikehara Y, et al.: Effect of early eradication on *Helicobacter pylori* related gastric carcinogenesis in Mongolian gerbils. *Cancer Sci* 2003; 94: 235-9.

Odum L, and Andersen LP.: Investigation of *Helicobacter pylori* ascorbic acid oxidatin; activity. *FEMS Immunol Med Microbiol* 1995;10:289-294

Ohana M, Okazaki K, Oshima C, et al.: Inhibitory effects of *Helicobacter pylori* infection o murine autoimmune gastritis. *Gut* 2003; 52:1102-1110.

Oken E, and Duggan C: Update on micronutrients: iron and zinc.*Curr Opin Pediatr.*2002 14:350-353.

Park CY, Kwak M, Gutierrez O, et al.: Comparison of genotyping *Helicobacter pylori* directl; from biopsy specimens and genotyping from bacterial cultures. *J Clin Microbiol* 2003; 41: 3336-8.

Parsonnet J, Friedman GD, Vandersteen DP, et al.: *Helicobacter pylori* infection and the risk o gastric carcinoma. *New Engl. J. Med.*1991; 325:1127-1131.

Peach HG, Bath NE, and Farish SJ.: *Helicobacter pylori* infection: an added stressor on iron status of women in the community. *Med J Aust.* 1998;169:188-90.

Peek RNI, Thompson SA, Atherton JC, et al.: Expression of iceA, a novel ulcer-associated *Helicobacter pylori* gene, is induced by contact with gastric epithelial cells and is associated with enhanced mucosal IL-8. *Gut* 1996; 39:A71.

Peng NJ, Lai KFI, Liu RS, et al.: Endoscopic ¹³C-urea breath test for the diagnosis o *Helicobacter pylori* infection. *Dig Liver Dis.*2002; 35: 73-77.

Perez-Paramo M, Albillos A, Calleja JL, et al.: Changes in gastrin and serum pepsinogens i monitoring of *Helicobacter pylori* response to therapy. *Dig Dis Sci* 1997; 42: 1734-1740.

Perez-Perez GI, and Israel DA: Role of iron in *Helicobacter pylori*: its influence in oute membrane protein expression and in pathogenicity. *Eur J Gastroenterol Hepatol.* 2000; 12:1263-5.

pylori antibodies in humans. *Ann. Intern. Med.* 1988; 109:11-17.

Perez-Perez GI, Rothenbacher D, and Brenner H: Epidemiology of *Helicobacter pylori* Infection. *Helicobacter* 2004; Suppl (9)1:1-6.

Perez-Perez GI: Role of *Helicobacter pylori* infection in the development of pernicious anemia. *Clin. Infect Dis.* 1997; 25:10202.

Perri F, Festa V, Clemente R, et al.: Randomized study of two "rescue" therapies for *Helicobacter pylori*-infected patients after failure of standard triple therapies. *Am J Gastroenterol* 2001; 96:58-62.

Perri F, Pastore M, Leandro G, et al.: *Helicobacter pylori* infection and growth delay in older children. *Arch Dis Child* 1997; 77:46-49.

Perri F, Villani MR, Quitadamo M, et al.: Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht trip therapy': a promising alternative to the quadruple therapy. *Aliment. Pharmacol Ther* 2001; 15:1017-1022.

Perri F: *Helicobacter pylori* infection: the diagnostic dilemma is still going on! *Dig. Liv. Dis* 2003; 35 (2):71-72.

Peters TM, Owen RJ, Slater E, et al.: Genetic diversity in the *Helicobacter pylori* CagA Pathogenicity Island and effect on expression of anti-CagA serum antibody in LTK patients with dyspepsia. *J Clin Pathol.* 2001; 54: 219 - 223.

Peterson WL, Ciociola AA, Sykes DL, et al.: Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating *H. pylori* and reducing ulcer recurrence. *Aliment Pharmacol. Ther.* 1996; 10:251-261.

Pietrangelo A: Physiology of iron transport and the hemochromatosis gene. *Am. J. Physiol.* 2002; 282: G403-414.

Pilotto A, Franceschi M, Leandro G, et al.: Influence of *Helicobacter pylori* infection on the severity of oesophagitis and response to therapy in the elderly. *Digest. Liver Dis.* 2002; 34: 328-331.

Podmore ID, Griffiths HR, Herbert KE, et al.: Vitamin C exhibits pro-oxidant properties. *Nature* 1998; 392:559.

Polat A, Cinel L, Dusmez D, et al.: Expression of cell-cycle related proteins in *Helicobacter pylori* gastritis and association with gastric carcinoma. *Neoplasms.* 2002; 49(2):95-100.

Ponzetto A, Pellicano R, Redaelli A, et al.: *Helicobacter pylori* infection in patients with Hepatitis C Virus positive chronic liver diseases. *New Microbiol* 2003; 26: 321-8.

Pountney DJ, Konijn AM, McKie AT, et al.: Iron proteins of duodenal enterocytes isolated from mice with genetically and experimentally altered iron metabolism. *Br J Haematol.* 1999; 105:1066-1073.